Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Ekaterina V Kurbatova"'
Autor:
Vincent K. Chang, Marjorie Z. Imperial, Patrick P. J. Phillips, Gustavo E. Velásquez, Payam Nahid, Andrew Vernon, Ekaterina V. Kurbatova, Susan Swindells, Richard E. Chaisson, Susan E. Dorman, John L. Johnson, Marc Weiner, Erin E. Sizemore, William Whitworth, Wendy Carr, Kia E. Bryant, Deron Burton, Kelly E. Dooley, Melissa Engle, Pheona Nsubuga, Andreas H. Diacon, Nguyen Viet Nhung, Rodney Dawson, Radojka M. Savic, AIDS Clinical Trial Group, Tuberculosis Trials Consortium
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-12 (2024)
Abstract The Phase 3 randomized controlled trial, TBTC Study 31/ACTG A5349 (NCT02410772) demonstrated that a 4-month rifapentine-moxifloxacin regimen for drug-susceptible pulmonary tuberculosis was safe and effective. The primary efficacy outcome was
Externí odkaz:
https://doaj.org/article/de940f5d4bbc4e00aaa1dfc2d65e721a
Autor:
Courtney M Yuen, Ekaterina V Kurbatova, Thelma Tupasi, Janice Campos Caoili, Martie Van Der Walt, Charlotte Kvasnovsky, Martin Yagui, Jaime Bayona, Carmen Contreras, Vaira Leimane, Julia Ershova, Laura E Via, HeeJin Kim, Somsak Akksilp, Boris Y Kazennyy, Grigory V Volchenkov, Ruwen Jou, Kai Kliiman, Olga V Demikhova, Irina A Vasilyeva, Tracy Dalton, J Peter Cegielski
Publikováno v:
PLoS Medicine, Vol 12, Iss 12, p e1001932 (2015)
BackgroundFor treating multidrug-resistant tuberculosis (MDR TB), the World Health Organization (WHO) recommends a regimen of at least four second-line drugs that are likely to be effective as well as pyrazinamide. WHO guidelines indicate only margin
Externí odkaz:
https://doaj.org/article/ace629e2383f4a7b89c77c4a3526dd6b
Publikováno v:
PLoS ONE, Vol 8, Iss 12, p e83006 (2013)
BackgroundDevelopment of resistance to antituberculosis drugs during treatment (i.e., acquired resistance) can lead to emergence of resistant strains and consequent poor clinical outcomes. However, it is unknown whether Mycobacterium tuberculosis com
Externí odkaz:
https://doaj.org/article/1a22faf0fe904398981757d91e3d2731
Publikováno v:
PLoS ONE, Vol 7, Iss 11, p e49355 (2012)
BACKGROUND: Foreign-born individuals comprise >50% of tuberculosis (TB) cases in the U.S. Since anti-TB drug resistance is more common in most other countries, when evaluating a foreign-born individual for TB, one must consider the risk of drug resis
Externí odkaz:
https://doaj.org/article/564b8f198054466cbe2785718d21e88a
Autor:
Ekaterina V. Kurbatova, Patrick P. J. Phillips, Susan E. Dorman, Erin E. Sizemore, Kia E. Bryant, Anne E. Purfield, Jessica Ricaldi, Nicole E. Brown, John L. Johnson, Carole L. Wallis, Joseph P. Akol, Oksana Ocheretina, Nguyen Van Hung, Harriet Mayanja-Kizza, Madeleine Lourens, Rodney Dawson, Nguyen Viet Nhung, Samuel Pierre, Yeukai Musodza, Justin Shenje, Sharlaa Badal-Faesen, Stalz Charles Vilbrun, Ziyaad Waja, Lakshmi Peddareddy, Nigel A. Scott, Yan Yuan, Stefan V. Goldberg, Susan Swindells, Richard E. Chaisson, Payam Nahid
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 207:1376-1382
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93c93ee24026cba6988eb4577b950ca4
https://doi.org/10.1164/rccm.202206-1118oc
https://doi.org/10.1164/rccm.202206-1118oc
Autor:
Anthony T Podany, Michelle Pham, Erin Sizemore, Neil Martinson, Wadzanai Samaneka, Lerato Mohapi, Sharlaa Badal-Faesen, Rod Dawson, John L Johnson, Harriet Mayanja, Umesh Lalloo, William C Whitworth, April Pettit, Kayla Campbell, Patrick P J Phillips, Kia Bryant, Nigel Scott, Andrew Vernon, Ekaterina V Kurbatova, Richard E Chaisson, Susan E Dorman, Payam Nahid, Susan Swindells, Kelly E Dooley, Courtney V Fletcher
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol 75, iss 4
Clin Infect Dis
Clin Infect Dis
Background A 4-month regimen containing rifapentine and moxifloxacin has noninferior efficacy compared to the standard 6-month regimen for drug-sensitive tuberculosis. We evaluated the effect of regimens containing daily, high-dose rifapentine on efa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17723c114dd6de4698d163d6fbb7ee29
https://escholarship.org/uc/item/4694p0w3
https://escholarship.org/uc/item/4694p0w3
Autor:
Anne E. Purfield, Nigel A. Scott, Samuel Pierre, Madeleine Lourens, Richard E. Chaisson, Melissa Engle, Payam Nahid, Erin Sizemore, Patrick P. J. Phillips, Ziyaad Waja, Kelly E. Dooley, Susan Swindells, Marc H Weiner, Ekaterina V. Kurbatova, Kim Narunsky, Radojka M. Savic, Susan E. Dorman, Sandy Nerette, Nhung Viet Nguyen, Wadzanai Samaneka, Ha T.T. Phan, James Hakim, Andrew Vernon, Thuong H. Pham, Grace Muzanyi, Stefan V. Goldberg, Justin Shenje, John L. Johnson, Neil A. Martinson, Kia E Bryant, Ian Sanne
Publikováno v:
The New England journal of medicine, vol 384, iss 18
BackgroundRifapentine-based regimens have potent antimycobacterial activity that may allow for a shorter course in patients with drug-susceptible pulmonary tuberculosis.MethodsIn an open-label, phase 3, randomized, controlled trial involving persons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3229ece147fe062e786e2a34a8ab15fd
https://escholarship.org/uc/item/30c34231
https://escholarship.org/uc/item/30c34231
Autor:
Kuo Wei Chiu, Kathleen Robergeau-Hunt, Pamela Fedrick, Anne E. Purfield, Mascha Elskamp, Yan Yuan, Nicole E Brown, Kim Narunsky, William C. Whitworth, Kimberley N Chapman Hedges, Ekaterina V. Kurbatova, Melissa Fagley, Erin Sizemore, Melissa Engle, Joanita Nassali, Cynthia Allen-Blige, Kumar Batra, Jessica N Ricaldi, Howard Davis, Kia E Bryant, Ha Phan, Mimi Phan
Publikováno v:
Contemp Clin Trials
Introduction With the growing use of online study management systems and rapid availability of data, timely data review and quality assessments are necessary to ensure proper clinical trial implementation. In this report we describe central monitorin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffebd0194dfb50408522d91d1abf0c15
https://pubmed.ncbi.nlm.nih.gov/33713841
https://pubmed.ncbi.nlm.nih.gov/33713841
Autor:
Martin S. Cetron, Xiaoyan Lu, Eric S. Halsey, Suxiang Tong, Krista Queen, Carolyn Herzig, Barbara Knust, Anna M. Acosta, Anna Uehara, Miwako Kobayashi, Megan J. Wallace, Rachel Murray, Farrell A Tobolowsky, Riley L Wagner, Yan Li, Ryan T. Novak, Cindy R. Friedman, Zachary D Schneider, Barbara J. Marston, Andrea Stewart, Clinton R. Paden, Jing Zhang, Mateusz M. Plucinski, Leah F. Moriarty, Atsuyoshi Ishizumi, Paul T. Cantey, William A. Bower, Alexandra M. Medley, Mitsuru Toda, Matthew R. Mauldin, Nicki Pesik, Ekaterina V. Kurbatova, Ying Tao, Christopher A. Elkins, Catherine H Bozio
Publikováno v:
Clinical Infectious Diseases
BackgroundThe Diamond Princess cruise ship was the site of a large outbreak of coronavirus disease 2019 (COVID-19). Of 437 Americans and their travel companions on the ship, 114 (26%) tested positive for severe acute respiratory syndrome coronavirus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::216dfbb052166352b044cc95fbe132d7
Autor:
Tatiana A. Kuznetsova, Dorothy A. Kaminski, Ekaterina V. Kurbatova, Natalia V. Kaunetis, J. Peter Cegielski, Eleanor M. Kerr, Grigory V. Volchenkov, Tatiana R. Somova, Julia Ershova, Irina Vasilyeva, Olga V. Demikhova, Larisa Chernousova
Publikováno v:
BMC Infectious Diseases
BMC Infectious Diseases, Vol 20, Iss 1, Pp 1-9 (2020)
BMC Infectious Diseases, Vol 20, Iss 1, Pp 1-9 (2020)
Background The main advantage of GeneXpert MTB/RIF® (Xpert) molecular diagnostic technology is the rapid detection of M.tuberculosis DNA and mutations associated with rifampicin (RIF) resistance for timely initiation of appropriate treatment and, co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb7be3cf8c68a628287cfe3255a62c75
http://europepmc.org/articles/PMC7382080
http://europepmc.org/articles/PMC7382080